Results: Advanced and moderate CRI independently predicted death (hazard ratio, 1.06; 95% confidence interval [CI], 1.01 to 1.12; and hazard ratio, 1.23; 95% CI, 1.18 to 1.29).
Severe anemia (hemoglobin level < 9.0 g/dL [<90 g/L]) also was an independent risk factor for death (hazard ratio, 1.38; 95% CI, 1.18 to 1.61).
The hazard rate was 4.04 (95% CI: 2.07 7.91), meaning that death hazard for a mouse in the non-treated AKI group was 4.04 times greater than for a mouse in the VLP-treated group.
Accordingly, we substituted the death hazard for GIST patients following treatment with imatinib mesylate with the death hazard function of the general population times 1.08 in our calculations.
Importantly, the death hazard was evident even in the lowest tertile of use.
Death hazard ratios for responders to non-responders were 0.91, 0.89, 0.79 and 0.73.
The death hazard rate without NB is about 2% for the first 40 days from admission.
The death hazard function depicted in Figure 1 is an example that has been calculated from Tables 1 and 2, and the death hazard of the general population (Supplementary Information Table I).
This resulted into a decrease down to 16.1% of the death hazard ratio, or inversely, more than six-fold increase of the death hazard ratio for those patients not showing the above-mentioned pattern for these three features.
There was not a significant difference in death hazard rates between religiously active and less active LDS.
However, there was a significant difference in death hazard rates between religiously active LDS and non-LDS.
